Efficacy and Safety of up to Two Years of Tralokinumab Treatment in Adults of Different Racial Subgroups With Moderate-to-Severe Atopic Dermatitis. J of Skin 2023, 7 (2), s144. https://doi.org/10.25251/skin.7.supp.144.